135 related articles for article (PubMed ID: 34105465)
21. Weakly supervised deep learning for determining the prognostic value of
Guo R; Hu X; Song H; Xu P; Xu H; Rominger A; Lin X; Menze B; Li B; Shi K
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3151-3161. PubMed ID: 33611614
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
Wang H; Shen G; Jiang C; Li L; Cui F; Tian R
PLoS One; 2018; 13(3):e0194435. PubMed ID: 29558489
[TBL] [Abstract][Full Text] [Related]
23. Appropriate timing to perform an interim
Wang R; Zhang Y; Fan Q; Jiang M; Zou L; Su M
Ann Hematol; 2024 Mar; 103(3):885-892. PubMed ID: 38030892
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of an
Wang H; Zhao S; Li L; Tian R
Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
[TBL] [Abstract][Full Text] [Related]
25. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study.
Jiang C; Liu J; Li L; Kosik RO; Su M; Zou L; Tian R
Nucl Med Commun; 2017 Nov; 38(11):937-947. PubMed ID: 28858180
[TBL] [Abstract][Full Text] [Related]
26. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
27. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
Toledano MN; Vera P; Tilly H; Jardin F; Becker S
PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
[TBL] [Abstract][Full Text] [Related]
28. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
31. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.
Bai B; Huang HQ; Cai QC; Fan W; Wang XX; Zhang X; Lin ZX; Gao Y; Xia YF; Guo Y; Cai QQ; Jiang WQ; Lin TY
Med Oncol; 2013 Mar; 30(1):339. PubMed ID: 23329306
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
34. [The Application Value of True Whole-body PET/CT Scanning Protocol in Patients of Extranodal NK/T Cell Lymphoma].
Li FL; Su MG; Shi DZ; Liang FL; Li L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 51(2):245-251. PubMed ID: 32220195
[TBL] [Abstract][Full Text] [Related]
35. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of whole-body dynamic
Yin J; Wang H; Zhu G; Chen N; Khan MI; Zhao Y
Heliyon; 2023 Sep; 9(9):e19749. PubMed ID: 37809527
[TBL] [Abstract][Full Text] [Related]
37. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
Cahu X; Bodet-Milin C; Brissot E; Maisonneuve H; Houot R; Morineau N; Solal-Celigny P; Godmer P; Gastinne T; Moreau P; Moreau A; Lamy T; Kraber-Bodere F; Le Gouill S
Ann Oncol; 2011 Mar; 22(3):705-711. PubMed ID: 20739714
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
39. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.
Zhou Z; Chen C; Li X; Li Z; Zhang X; Chang Y; Lu L; Cui Y; Ma Y; Zhang M
Ann Hematol; 2015 Jun; 94(6):963-7. PubMed ID: 25547320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
